2,700
Participants
Start Date
June 30, 2011
Primary Completion Date
April 4, 2019
Study Completion Date
April 4, 2019
CYP2C19 genotyping
CYP2C19 genotyping will be performed in the intervention group. In patients with \*1/\*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (\*2 or \*3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
OLV Hospital, Aalst
University of Naples Federico II, Naples
Meander Medisch Centrum, Amersfoort
OLVG, Amsterdam
Rijnstate Hospital, Arnhem
Amphia Hospital, Breda
University Medical Center Groningen, Groningen
St. Antonius Hospital, Nieuwegein
University Medical Center, Utrecht
Isala Klinieken, Zwolle
Collaborators (1)
Isala
OTHER
Meander Medical Center
OTHER
UMC Utrecht
OTHER
University Medical Center Groningen
OTHER
OLVG
NETWORK
Onze Lieve Vrouw Hospital
OTHER
Amphia Hospital
OTHER
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Federico II University
OTHER
Rijnstate Hospital
OTHER
Vera HM Deneer
OTHER